Generic Injectables Market Opportunity Assessment, Market Challenges, Key vendor analysis, Vendor landscape by 2028
Market Highlights
It is estimated that the global generic injectables market
is expected to register a CAGR ~13% during the forecast period of 2018–2023.
Generic injectables is a key feedstock in pharmaceutical, diagnostics,
biotechnology, diagnostic, and veterinary industries.
The Americas generic
injectables market is expected to witness tremendous growth owing to the
expansion of biosimilar products with off patenting of the major patented drugs
is expected to drive growth of generic sterile injectable market during
forecast period. For example, the loss of patent in 2017 for blockbuster brands
such as Cancidas, Remicade, Cubicin, Invanz and Humira leading to entry of
generic products. is also expected to drive the market. Other key factors such
as the untapped market opportunities in emerging countries, growing investments
by government organizations are contributing towards the growth of the market.
However, in the negative perception of the consumers towards generic drugs
coupled with stringent regulations laid down by the governments are few factors
restraining the growth of the market.
On the regional basis, the generic injectables market in the
Americas is predicted to dominate the market during the forecast period. The
North American region holds substantial share in the global market. Unlike
branded drug manufacturers that invest huge amount of capital on R&D and
marketing, generic drug manufacturers do not require such investments.
Furthermore, the number of competitors in the generic injectables market is
lower as compared to oral generics, resulting in limited price erosion and significantly
higher profit margins.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/7512
Currently, the global generic injectables market is
dominated by numerous players. The major players in this market are involved in
new product launches, strategic partnerships and collaborations to increase
their product portfolio. For instance, in December 2016, Baxter acquired
injectables from Claris for the production of injectable medicines such as
anesthesia and analgesics, anti-infective, renal, and critical care
medications.
The global generic injectables market is segmented on the
basis of product type, container, application, and distribution channel.
Some of the key players in the global generic injectables
market are Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE &
Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma
Pharmaceuticals plc, Lupin Ltd., Sanofi, Biocon, Dr. Reddy’s Laboratories,
Aurobindo Pharma, Sagent Pharmaceuticals Inc., Zydus Cadila, GlaxoSmithKline
plc, AstraZeneca plc., among others.
Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/generic-injectables-market-7512
At Market Research Future (MRFR), we enable our customers
to unravel the complexity of various industries through our Cooked Research
Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients. Our market research studies by
Components, Application, Logistics and market players for global, regional, and
country level market segments, enable our clients to see more, know more, and
do more, which help to answer all their most important questions.
Contact:
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America
Phone:
+1 628 258 0071(US)
+44 2035 002 764(UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
Comments
Post a Comment